Quick Answer
X4 Pharmaceuticals, Inc reported Total Assets of $290.46 million for the year ending 2025.
- X4 Pharmaceuticals, Inc showed an increase of +98.3% in Total Assets from 2024 to 2025.
- This data is from X4 Pharmaceuticals, Inc's annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $69.22 million | Q2 2018: $57.21 million | Q3 2018: $45.90 million | Q1 2019: $62.55 million | Q2 2019: $133.51 million | Q3 2019: $109.54 million | Q1 2020: $153.72 million | Q2 2020: $142.53 million | Q3 2020: $133.13 million | Q1 2021: $161.04 million | Q2 2021: $141.66 million | Q3 2021: $120.52 million | Q1 2022: $99.63 million | Q2 2022: $81.02 million | Q3 2022: $113.41 million | Q1 2023: $124.41 million | Q2 2023: $173.40 million | Q3 2023: $173.29 million | Q1 2024: $112.18 million | Q2 2024: $210.61 million | Q3 2024: $178.17 million | Q1 2025: $130.01 million | Q2 2025: $105.17 million | Q3 2025: $163.56 million.
- Over the full 9 years of available data (2017 to 2025), X4 Pharmaceuticals, Inc's Total Assets has grown by 257.5%.
- Historical annual values: Fiscal year 2025: $290.46 million | Fiscal year 2024: $146.45 million | Fiscal year 2023: $147.26 million | Fiscal year 2022: $155.59 million | Fiscal year 2021: $117.18 million | Fiscal year 2020: $122.87 million | Fiscal year 2019: $160.70 million | Fiscal year 2018: $9.94 million | Fiscal year 2017: $81.25 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: